Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
Eli Lilly and Co. said Monday it will spend $72 million to upgrade a diabetes manufacturing operation at one of its Indianapolis facilities, the second major project of that kind announced this year.
The Indianapolis-based drugmaker will use the money to replace an existing insulin-vial-filling line with new technology. The upgraded line will fill vials with Humalog and Humulin brands of insulin—two of Lilly’s oldest products—and to prepare for new insulin products.
“Our company is poised for continued growth, and diabetes represents one of our key therapeutic areas,” CEO David Ricks said in a statement. “Investments such as this are vital to ensuring we continue meeting the needs of people who use our medicines.”
The investment is on top of $85 million that Lilly announced in March it would spend to expand a manufacturing operation at the Lilly Technology Center southwest of downtown that assembles Trulicity injection pens for diabetes patients.
Over the past five years, Lilly has added about 400 jobs in the city for U.S. diabetes manufacturing. The firm said Monday morning that the $72 million project would not result in any new jobs.
In all, Lilly plans to spend about $850 million this year on capital projects at its U.S. research labs, manufacturing operations and other facilities.
Lilly has invested more than $1.2 billion since 2012 to boost its U.S. diabetes product manufacturing operations.
Please enable JavaScript to view this content.